English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

AIM: To investigate the effects of Yiqi Huoxue Ruan j i an J i edu (YHRJ) decoc t ion on the expression of apoptosis-related genes Fas, FasL, Bcl-2, Bax, P53 and NF-kB in human hepatocellular carcinoma cell line BEL-7402. METHODS: Human hepatocellular carcinoma BEL-7402 cells were divided into 6 groups, and treated with normal saline (NS), NS plus cisplatin (DDP), equal-dose YHRJ decoction, YHRJ decoction plus DDP group, high-dose YHRJ decoction, high-dose YHRJ decoction plus DDP, respectively. Flow cytometry, immunohistochemistry, in situ hybridization, and reverse transcription-polymerase chain reaction (RTPCR) were used to analyze the expression of Fas, FasL, Bcl-2, Bax, P53 and NF-kB. RESULTS: Flow cytometry revealed a dramatic increase of Fas expression in the cells treated with NS plus DDP, equal-dose YHRJ and equaldose YHRJ plus DDP, and high-dose YHRJ plus DDP in comparison with that in the control cells (30.12% ± 22.94%, 10.50% ± 8.41%, 30.35% ± 22.98%, 32.61% ± 26.87% vs 8.77% ± 6.93%, P < 0.01), but not in the cells treated with high-dose YHRJ (P > 0.05). The expression of FasL was significantly higher in NS+DDP and YHRJD+DDP treatment group than that in the normal controls (16.40% ± 7.168%, 8.41% ± 6.74% vs 4.12% ± 2.60%, P < 0.01), but lower in high-dose YHRJ group (3.05% ± 2.53% vs 4.12% ± 2.60%, P < 0.01). Immunohistochemistry showed a significant decrease of P53 expression in all the drug-treated cells (30.2%, 14.6%, 19.8%, 17.3% vs 60.0%, P < 0.05) except high-dose YHRJ plus DDP treated ones; The expression of Bax protein in all the drug-treated cells was higher significantly than that in the controls (40.7%, 40.4%, 72.1%, 68.9%, 42.2% vs 30.0%, P < 0.05); There was a notable decrease of Bcl-2 expression in NS plus DDP and high-dose YHRJ treated cells (26.3%, 24.4% vs 30.5%, P < 0.05) as well as of NF-kB expression in all the drug-treated cells (40.7%, 40.4%, 72.1%, 68.9%, 42.2% vs 30.0%, P < 0.05). In situ hybridization also demonstrated that the mRNA expression of NF-kB was markedly decreased in all the drug-treated groups as compared with that in the control group (30.5%, 13.3%, 21.4%, 17.4%, 53.2% vs 58%, P < 0.05). RT-PCR revealed a significant decrease of Bcl-2 mRNA expression in equal-dose YHRJ treated cells (0.717 ± 0.198 vs 1.327 ± 0.097, P < 0.001) as well as a dramatic increase of Bax mRNA expression in DDP, YHRJD, and YHRJG treated cells (46.22 ± 6.22, 56.19 ± 7.36, 62.32 ± 11.06 vs 35.22 ± 4.38, P < 0.05). CONCLUSION: YHRJ decoction may induce apoptosis in human hepatocellular carcinoma

shijie huaren xiaohua zazhi

<i>Yiqi Huoxue Ruanjian Jiedu</i> decoction regulates expression and activity of apoptosis-regulated genes in human hepatocellular carcinoma cell line BEL-7402

Yiqi Huoxue Ruanjian Jiedu decoction regulates expression and activity of apoptosis-regulated genes in human hepatocellular carcinoma cell line BEL-7402